If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Through pilot project funding, multidisciplinary mentorship, educational seminars, career development programs, and collaborative research opportunities, the Center provides early-stage investigators with the resources necessary to establish independent research programs. Junior faculty benefit from access to experienced mentors across multiple disciplines, specialized research cores, and opportunities to participate in multicenter studies and national collaborations. These efforts are closely integrated with the Barshop Institute's NIH-funded Biology of Aging Training Program (T32), creating a comprehensive environment for training predoctoral students, postdoctoral fellows, clinical fellows, and junior faculty in translational geroscience and geriatrics.
=== 1970s === 1970: Australian geologist and palaeontologist Dorothy Hill became the first female president of the Australian Academy of Science. 1970: New Zealand geologist and palynologist Rosemary Askin the first New Zealand woman to undertake her own research programme in Antarctica. 1970: Spanish biochemist Margarita Salas discovered and characterized the Φ29 phage DNA polymerase. She was also the first scientific woman elected to the Royal Spanish Academy and was the first woman recipient of the Carlos J. Finlay Prize for Microbiology. 1970: Samira Islam became the first Saudi Arabian person to earn a PhD in pharmacology. 1970: American astronomer Vera Rubin published the first evidence for dark matter. 1970: Polish geologist Franciszka Szymakowska became widely known because of her unique and detailed geological drawings that are still used today. 1971: Romanian chemist Ecaterina Ciorănescu-Nenițescu became a member of the New York Chemical Society. She was noted for developing synthesis processes for antituberculosis drugs and insecticides and creating new substances using cytostatic grafting. 1973: American physicist Anna Coble became the first African-American woman to receive a PhD in biophysics, completing her dissertation at University of Illinois. 1974: Dominican marine biologist Idelisa Bonnelly founded the Dominican Republic Academy of Science. 1975: Indian chemist Asima Chatterjee was elected the General President of the Indian Science Congress Association. She simultaneously became the first female scientist ever elected a member of the congress.
22 November – With Storm Bert set to arrive in Scotland the following day, bringing snow and ice, Police Scotland urges motorists not to travel. 23 November – Police Scotland arrest seven people in connection with Bonfire Night disturbances in the Pollokshields area of Glasgow. 24 November – Alex Cole-Hamilton, the leader of the Scottish Liberal Democrats says his party will vote down the Scottish Government's upcoming budget if it contains even a "penny" promoting Scottish independence. Police charge a senior British Army officer over an incident during which he took decommissioned hand grenades through security at Edinburgh Airport on 16 October. 25 November – 50 non-essential workers are evacuated from the Valaris 120 oil rig 150 miles off the coast of Aberdeen following a crash with a vessel. 26 November – Aberdeen Football Club withdraws an application for a temporary alcohol licence. 27 November – The Scottish Government launches a public consultation on potential sped limit changes that could see the speed limit reduced from 60 mph to 50 mph for cars on single carriageways, but increased from 40 mph to 50 mph for HGV vehicles. HGVs could also have speed limits on dual carriageways increased to 60 mph. 28 November – The Scottish Government announces that all pensioner households will receive a Winter Fuel Payment from Winter 2025–26, with those on Pension Credit receiving £200 or £300 dependent on age and the rest receiving £100. The Scottish Government abandons plans to upgrade the A96 between Aberdeen and Inverness to make it a full dual carriageway by 2030.
Sources: en.wikipedia.org
Archival Resources Details Thorburn Brailsford Robertson: Repository: Commonwealth Scientific and Industrial Research Organisation (CSIRO) Corporate Records and Archives Strategies, The Encyclopedia of Australian Science and Innovation. Robertson, Thorburn Brailsford (1884–1930), The Encyclopedia of Australian Science and Innovation. Thorburn Brailsford Robertson, Adelaide Connect, University of Adelaide. Lehmann Jayne, "World Diabetes Day – Time to celebrate Adelaide’s link to 1922 insulin discovery", EdHealth Australia, 14 November 2016. Thorburn Brailsford Robertson, South Australian Medical Heritage Society. TROVE: "From the library of Thorburn Brailsford Robertson".
=== Separation === Most commercial 99Mo/99mTc generators use column chromatography, in which 99Mo in the form of molybdate, MoO42− is adsorbed onto acid alumina (Al2O3). When the 99Mo decays it forms pertechnetate TcO4−, which, because of its single charge, is less tightly bound to the alumina. Pouring normal saline solution through the column of immobilized 99Mo elutes the soluble 99mTc, resulting in a saline solution containing the 99mTc as pertechnetate, with sodium as the counterion. The solution of sodium pertechnetate may then be added in an appropriate concentration to the pharmaceutical kit to be used, or sodium pertechnetate can be used directly without pharmaceutical tagging for specific procedures requiring only the 99mTcO4− as the primary radiopharmaceutical. A large percentage of the 99mTc generated by a 99Mo/99mTc generator is produced in the first 3 parent half-lives, or approximately one week. Hence, clinical nuclear medicine units purchase at least one such generator per week or order several in a staggered fashion.
SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium/glucose cotransporter 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. As of 2014, several medications of this class had been approved or were under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.
Narcotics in Bolivia, South America, is a subject that primarily involves the coca crop, used in the production of the drug, cocaine. Trafficking and corruption have been two of the most prominent negative side-effects of the illicit narcotics trade in Bolivia and the country's government has engaged in negotiations with the United States (US) as result of the industry's ramifications.
Sources: en.wikipedia.org
=== India === In India, Entamoeba is the most common cause of food illness, followed by Campylobacter bacteria, Salmonella bacteria, E. coli bacteria, and norovirus. According to statistics, food poisoning was the second most common cause of infectious disease outbreak in India in 2017. The numbers of outbreaks have increased from 50 in 2008 to 242 in 2017.
=== Other countries === The flag was used in the Gaza war protests, such as in London in November 2023 and in Italy in September–October 2025. The flag was flown by some protesters during the Trillion Peso March which was against corruption and the "ghost projects" controversy in the Philippines, During another protest in the Philippines on 12 October, a motorcycle rider carrying the flag was confronted by other protestors who suspected him of being a provocateur, and he was escorted away by police. and by university students protesting lifetime pensions for parliament members in East Timor. During the French anti-government Bloquons tout protests in September 2025 after the fall of the Bayrou government, some protesters carried the flag. The flag was present during the 2025 Peruvian protests, where the flag was once again used by demonstrators protesting against pension reforms in Peru by the government of Dina Boluarte. Specifically, the flag was present again during the protest on 24 September in Plaza San Martín, Lima. Anti-government protesters in Asunción, Paraguay, in late September along with protesters at La Paz demanding an audit for the 2025 Bolivian general election in October also carried the flag. Gen Z protesters in Morocco used the flag. British magazine The Week noted the flag's presence in protests in New York, Rome, and Slovakia.
== Venture arms == SR One was established in 1985, by SmithKline Beecham to invest in new biotechnology companies and continued operating after GSK was formed; by 2003, GSK had formed another subsidiary, GSK Ventures, to out-license or start new companies around drug candidates that it did not intend to develop further. As of 2003, SR One tended to invest only if the company aligned with GSK's business. In September 2019, Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. This includes its transglutaminase 2 (TG2) small molecule program for the treatment of celiac disease.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.